JP5619614B2 - レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 - Google Patents
レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 Download PDFInfo
- Publication number
- JP5619614B2 JP5619614B2 JP2010534547A JP2010534547A JP5619614B2 JP 5619614 B2 JP5619614 B2 JP 5619614B2 JP 2010534547 A JP2010534547 A JP 2010534547A JP 2010534547 A JP2010534547 A JP 2010534547A JP 5619614 B2 JP5619614 B2 JP 5619614B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- btv
- viral
- cells
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title claims description 196
- 229960005486 vaccine Drugs 0.000 title claims description 57
- 241000702247 Reoviridae Species 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 210000004027 cell Anatomy 0.000 claims description 176
- 241000120506 Bluetongue virus Species 0.000 claims description 138
- 230000003612 virological effect Effects 0.000 claims description 92
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 80
- 238000001890 transfection Methods 0.000 claims description 78
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 64
- 230000035772 mutation Effects 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 108700039887 Essential Genes Proteins 0.000 claims description 29
- 239000002299 complementary DNA Substances 0.000 claims description 26
- 230000006870 function Effects 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000010076 replication Effects 0.000 claims description 21
- 238000012216 screening Methods 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 12
- 230000035897 transcription Effects 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 241000702259 Orbivirus Species 0.000 claims description 9
- 108700005077 Viral Genes Proteins 0.000 claims description 9
- 210000000234 capsid Anatomy 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 241000702670 Rotavirus Species 0.000 claims description 8
- 241000120516 African horse sickness virus Species 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 241000150278 Seoul orthohantavirus Species 0.000 claims description 4
- 108060004795 Methyltransferase Proteins 0.000 claims description 3
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 55
- 101150057777 Segment-10 gene Proteins 0.000 description 46
- 238000011084 recovery Methods 0.000 description 40
- 208000015181 infectious disease Diseases 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 36
- 239000013612 plasmid Substances 0.000 description 30
- 239000003550 marker Substances 0.000 description 28
- 230000002441 reversible effect Effects 0.000 description 26
- 230000002458 infectious effect Effects 0.000 description 25
- 230000000295 complement effect Effects 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 22
- 101710144111 Non-structural protein 3 Proteins 0.000 description 21
- 239000000499 gel Substances 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 238000013459 approach Methods 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 108010067390 Viral Proteins Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 101710081079 Minor spike protein H Proteins 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 241000238631 Hexapoda Species 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- 229920002401 polyacrylamide Polymers 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002356 single layer Substances 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000008303 genetic mechanism Effects 0.000 description 8
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 238000012761 co-transfection Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000702263 Reovirus sp. Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101710128560 Initiator protein NS1 Proteins 0.000 description 5
- 101710144127 Non-structural protein 1 Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 208000003836 bluetongue Diseases 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 4
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001042466 Mammalian orthoreovirus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 210000000605 viral structure Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710144128 Non-structural protein 2 Proteins 0.000 description 3
- 101710199667 Nuclear export protein Proteins 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000007771 core particle Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000282817 Bovidae Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 241001331845 Equus asinus x caballus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101150038760 Ns3 gene Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- -1 for example Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- IDSXLJLXYMLSJM-UHFFFAOYSA-N morpholine;propane-1-sulfonic acid Chemical compound C1COCCN1.CCCS(O)(=O)=O IDSXLJLXYMLSJM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical group C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000006770 Endosomal Sorting Complexes Required for Transport Human genes 0.000 description 1
- 108010086672 Endosomal Sorting Complexes Required for Transport Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101800000511 Non-structural protein 2 Proteins 0.000 description 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101710093906 Outer capsid protein VP2 Proteins 0.000 description 1
- 101710093982 Outer capsid protein VP5 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710136311 Protein VP6 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000008104 Reoviridae Infections Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710174009 Suppressor of RNA silencing p3 Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 108700010850 rotavirus proteins Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12151—Methods of production or purification of viral material
- C12N2720/12152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
必須遺伝子の機能が破壊されるようにレオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルス一本鎖RNA(ssRNA)を細胞に形質移入するステップと、
前記ワクチン用ウイルス株の製造を導くための適切な条件下で形質移入された前記細胞を培養するステップと
を含み、前記細胞が、前記必須ウイルス遺伝子の機能を補完し、それによりワクチン用ウイルス株の前記細胞内での複製を可能にする方法を提供する。
(1)第1の形質移入ステップは、ウイルスカプシドの内層の組み立てに必要な成分を少なくともコードするssRNAを細胞に形質移入することを含み、
(2)第2の形質移入ステップは、ウイルスゲノムの転写産物であり、変異を含み、したがってウイルスの組み立てに必要な全ての成分をコードするssRNAを細胞に形質移入することを含む。
遺伝子の機能が破壊されるようにレオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルスssRNAを細胞に形質移入するステップと、
適切な条件下で形質移入された前記細胞を培養するステップと
を含み、形質移入された前記細胞を培養した後に産生されるウイルスが病原性であれば、前記ウイルス遺伝子が必須遺伝子でない方法も提供する。
レオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルス一本鎖RNA(ssRNA)を細胞に形質移入するステップと、
前記改変ウイルス株の製造を導くために適切な条件下で形質移入された前記細胞を培養するステップと
を含み、前記細胞が、前記改変ウイルス株の前記細胞内での複製を可能にする方法も提供する。
(1)第1の形質移入ステップは、ウイルスカプシドの内層の組み立てに必要な成分を少なくともコードするssRNAを細胞に形質移入することを含み、
(2)第2の形質移入ステップは、ウイルスゲノムの転写産物であり、変異も含み、したがってウイルスの組み立てに必要な全ての成分をコードするssRNAを細胞に形質移入することを含む。
株化細胞およびウイルス。BSR細胞(BHK−21のクローン)を、5%v/v胎児ウシ血清(FBS)を補ったダルベッコ改変イーグル培地(DMEM)中で、35℃にて5%CO2中で培養した。
(5’CTACTAGTGGCTGCTGTGGTAGCGCTGCTGACATCAGTTTG3’)およびS10_mt_Hae_409R
(5’CAAACTGATGTCAGCAGCGCTACCACAGCAGCCACTAGTAG3’)。pBTV1S8Bglを野生型BTV−1 S8クローンから作製するために用いた突然変異誘発プライマー:5’BTV1_S8_BglII
(5’GATTTACCAGGTGTGATGAGATCTAACTACGATGTTCGTGAAC3’)および3’BTV1_S8_BglII
(5’CGAACATCGTAGTTAGATCTCATCACACCTGGTAAATCGGGC3’)。突然変異誘発塩基に下線を引き、制限部位を太字で示す。
BTV10_S10_259F(5’GGAGAAGGCTGCATTCGCATCG3’)、BTV10_S10_611R(5’CTCATCCTCACTGCGTCATTATATGATTGTTTTTTCATCACTTC3’)。
EcoT7_S9_F
(5’CTAGGAATTCTAATACGACTCACTATAGTTAAAAAATCGCATATGTCAGCTGC3’)。
EcoBsmB_S9_R
(5’CAGTGAATTCGTCTCCGTAAGTGTAAAATCGCCCTACG3’)
BTV1S10T7EcoRI(5’CGGAATTCTAATACGACTCACTATAGTTAAAAAGTGTCGCTGCCATGCTA3’)
NS3BsmBi rev(5’GTAAGTGTGTAGTATCGCGCACC3’)
プラスミド由来T7転写産物からのブルータングウイルス回収の効率を増大させる2つの変更を行った。これらの変更はともに、上記の形質移入方法に対する変化である。それぞれの改良は、プラスミド由来転写産物からのウイルスの回収効率をおよそ10倍増大させ、併せておよそ100倍のウイルスの回収の増大をもたらす。
細胞に、上記のように、それぞれの場合に10個のプラスミド由来転写産物の完全セットを2回(1回ではなく)形質移入する。形質移入は18時間の間隔で行い、単一形質移入を用いる場合のおよそ10倍にウイルス回収が増大する。二重形質移入方法を用いるウイルスの回収の増大は、BTVコアから作製したssRNAを用いた場合(図18)と、10個のcDNAクローンから作製したT7転写産物の完全セットを用いた場合(図19)とで観察された。
細胞に、改変番号1と同様であるが、ゲノムセグメント2、5、7および10をコードするT7転写産物を第1の形質移入から削除して2回形質移入した。第2の形質移入は、10個の転写産物の完全セットを用いる。形質移入は18時間の間隔で行い、上記の二重形質移入を用いる場合のおよそ10倍にウイルス回収がさらに増大する(図20)。
上記の2つのアプローチは、真のウイルス転写産物とT7転写産物の混合物、またはT7転写産物の完全ゲノムセットのいずれかを用いる、BTVについての代替の逆遺伝学的機構を示す。これらにより、BTV転写産物を許容細胞に形質移入するために用いたときにこれらの転写産物が感染性である[1]という発見を拡張し、5’末端のキャップアナログを有するin vitro合成T7転写産物がコア粒子により合成された転写産物を機能的に置換できることを示す。
1. Boyce, M. and Roy, P. 2007. Recovery of Infectious Bluetongue Virus from RNA. J. Virol. 81(5): 2179-2186.
2. Komoto, S., J. Sasaki, and K. Taniguchi. 2006. Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus. Proc, Natl. Acad. ScL USA 103:4646-4651.
3. Roner, M. R., and W. K. Joklik. 2001. Reovirus reverse genetics: incorporation of the CAT gene into the reovirus genome. Proc. Natl. Acad. Sci. USA 98:8036-8041.
4. Kobayashi, T., et al. 2007 A Reverse Genetics System for dsRNA Viruses. Cell Host & Microbe. 1(2): 147-157.
5. Roy, P., Towards the control of emerging Bluetongue disease. 1991, London: Oxford Virology. 1-71.
6. Patton, J.T., Rotavirus VPl alone specifically binds to the 3' end of viral mRNA, but the interaction is not sufficient to initiate minus-strand synthesis. J. Virol, 1996. 70(11): p. 7940-7.
7. Patton, J. T., et al., cis-Acting signals that promote genome replication in rotavirus mRNA. J. Virol, 1996. 70(6): p. 3961-71.
8. Poncet, D., C. Aponte, and J. Cohen, Rotavirus protein NSP3 (NS34) is bound to the 3' end consensus sequence of viral mRNAs in infected cells. J. Virol, 1993. 67(6): p. 3159-65.
9. Chizhikov, V. and J.T. Patton, A four-nucleotide translation enhancer in the 3'- terminal consensus sequence of the nonpolyadenylated mRNAs of rotavirus. RNA, 2000. 6(6): p. 814-25.
10. Roner, M.R., K. Bassett, and J. Roehr, Identification of the 5' sequences required for incorporation of an engineered ssRNA into the Reovirus genome. Virology, 2004. 329(2): p. 348-60.
11. Roner, M. R. and J. Roehr, The 3' sequences required for incorporation of an engineered ssRNA into the Reovirus genome. Virol J, 2006. 3: p. 1.
12. Roner, M.R. and B. G. Steele, Localizing the reovirus packaging signals using an engineered ml and s2 ssRNA. Virology, 2007. 358(1): p. 89-97.
13. Fuerst, T.R. and B. Moss, Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cells. Importance of the 5' untranslated leader. J MoI Biol, 1989. 206(2): p. 333-48.
14. Muthukrishnan, S., et al., 5'-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. Nature, 1975. 255: p. 33-37.
15. Wirblich, C, B. Bhattacharya, and P. Roy, Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein TsglOl. J. Virol. 2006. 80(1): p. 460-73.
16. Bhattacharya, B., RJ. Noad, and P. Roy, Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress. Virol J, 2007. Jan 15; 4:7.
17. Weiner M. P., C, G.L., Schoelttin, W., Cline, J., Mathur, E., amd Bauer, J.C., Site directed mutagenesis of double stranded DNA by the polymerase chain reaction. Gene, 1994. 151: p. 119-123.
18. Maan, S., S. Rao, N. S. Maan, S. J. Anthony, H. Attoui, A. R. Samuel, and P. P. Mertens. 2007. Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses. J. Virol. Methods 143:132-9.
19. Sambrook, J., and D. W. Russell. 2001. Molecular Cloning: a laboratory manual, 3rd ed. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY.
20. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain- terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74:5463-7.
21. Kahlon, J., K. Sugiyama, and P. Roy. 1983. Molecular basis of bluetongue virus neutralization. J. Virol. 48:627-32.
22. Yanisch-Perron, C5 J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectors. Gene 33:103-19.
23. Loudon, P. T., T. Hirasawa, S. Oldfield, M. Murphy, and P. Roy. 1991. Expression of the outer capsid protein VP5 of two bluetongue viruses, and synthesis of chimeric double-shelled virus-like particles using combinations of recombinant baculoviruses. Virology 182:793-801.
24. Roy, P., B. D.H.L., H. LeBlois, and B. J. Erasmus. 1994. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: Evidence for homologous and partial heterologous protection. Vaccine 12:805-811.
25. Cui, S., K. Eisenacher, A. Kirchhofer, K. Brzozka, A. Lammens, K. Lammens, T. Fujita, K. K. Conzelmann, A. Krug, and K. P. Hopfner. 2008. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. MoI. Cell 29:169-79.
26. Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, S. Endres, and G. Hartmann. 2006. 5'- Triphosphate RNA is the ligand for RIG-I. Science 314:994-7.
27. Pichlmair, A., O. Schulz, C. P. Tan, T. I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5 '-phosphates. Science 314:997-1001.
28. Plumet, S., F. Herschke, J. M. Bourhis, H. Valentin, S. Longhi, and D. Gerlier. 2007. Cytosolic 5 '-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. PLoS ONE 2:e279.
29. Tani, H. et al., Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C vims envelope proteins. J Virol 81 (16), 8601 (2007).
Claims (15)
- レオウイルス科の一員であるウイルスのワクチン用ウイルス株を製造する方法であって、
必須遺伝子の機能が破壊されるようにレオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルス一本鎖RNA(ssRNA)を細胞に形質移入するステップと、
前記ワクチン用ウイルス株の製造を導くために適切な条件下で形質移入された前記細胞を培養するステップと
を含み、
前記細胞が、前記必須ウイルス遺伝子の機能を補完し、それによりワクチン用ウイルス株の前記細胞内での複製を可能にし、
前記の細胞に形質移入するステップが、
(1)第1の形質移入ステップが、ウイルスカプシドの内層の組み立てに必要な成分をコードするssRNAを細胞に形質移入することを含むものであり、
(2)第2の形質移入ステップが、ウイルスゲノムの転写産物であり、前記変異を含み、前記ウイルスの組み立てに必要な全ての成分をコードするssRNAを細胞に形質移入することを含むものである、2以上の形質移入ステップを含む、方法。 - 第1と第2の形質移入ステップの間に少なくとも6時間の間隔がある、請求項1に記載の方法。
- 前記ウイルスが、ロタウイルス属またはオルビウイルス属の一員である、請求項1または2に記載の方法。
- 前記ウイルスが、ブルータングウイルス、アフリカ馬疫ウイルスまたは流行性出血熱ウイルスである請求項1または2に記載の方法。
- 前記ウイルスがブルータングウイルスである、請求項1または2に記載の方法。
- 前記ssRNAの一部分が、前記変異を含むウイルスゲノムのcDNAクローンの転写産物である、請求項1〜5のいずれか一項に記載の方法。
- ssRNAが全て、前記変異を含むウイルスゲノムのcDNAクローンの転写産物である、請求項1〜5のいずれか一項に記載の方法。
- 複数の必須遺伝子の機能が破壊される、請求項1〜7のいずれか一項に記載の方法。
- 前記必須遺伝子が、ポリメラーゼ、ヘリカーゼ、キャップ形成酵素または非構造タンパク質である、請求項1〜8のいずれか一項に記載の方法。
- 前記細胞が、ssRNAの形質移入に適し、かつ、BHK 21細胞、Vero細胞、293T細胞、BSR細胞、HeLa細胞、C6/36細胞またはKC細胞などのウイルス株の培養に適する、請求項1〜9のいずれか一項に記載の方法。
- 細胞に形質移入するために用いられるウイルスssRNAが、単離ssRNAである、請求項1〜10のいずれか一項に記載の方法。
- ワクチン用ウイルス株を細胞から単離するステップをさらに含む、請求項1〜11のいずれか一項に記載の方法。
- レオウイルス科の一員であるウイルスの必須遺伝子を同定するためのスクリーニング方法であって、
遺伝子の機能が破壊されるようにレオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルスssRNAを細胞に形質移入するステップと、
適切な条件下で形質移入された前記細胞を培養するステップと
を含み、
形質移入された前記細胞を培養した後に産生されるウイルスが病原性であれば、前記ウイルス遺伝子が必須遺伝子でなく、
前記の細胞に形質移入するステップが、
(1)第1の形質移入ステップが、ウイルスカプシドの内層の組み立てに必要な成分をコードするssRNAを細胞に形質移入することを含むものであり、
(2)第2の形質移入ステップが、ウイルスゲノムの転写産物であり、前記変異を含み、前記ウイルスの組み立てに必要な全ての成分をコードするssRNAを細胞に形質移入することを含むものである、2以上の形質移入ステップを含む、方法。 - レオウイルス科の一員であるウイルスの改変ウイルス株を製造する方法であって、
レオウイルス科のウイルスに変異を導入するステップと、
前記ウイルスのゲノムに由来し、前記変異を含むウイルス一本鎖RNA(ssRNA)を細胞に形質移入するステップと、
前記改変ウイルス株の製造を導くために適切な条件下で形質移入された前記細胞を培養するステップと
を含み、
前記細胞が、前記改変ウイルス株の細胞内での複製を可能にし、
前記の細胞に形質移入するステップが、
(1)第1の形質移入ステップが、ウイルスカプシドの内層の組み立てに必要な成分をコードするssRNAを細胞に形質移入することを含むものであり、
(2)第2の形質移入ステップが、ウイルスゲノムの転写産物であり、前記変異を含み、前記ウイルスの組み立てに必要な全ての成分をコードするssRNAを細胞に形質移入することを含むものである、2以上の形質移入ステップを含む、方法。 - 第1と第2の形質移入ステップの間に少なくとも6時間の間隔がある、請求項13に記載のスクリーニング方法または請求項14に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98999107P | 2007-11-26 | 2007-11-26 | |
US60/989,991 | 2007-11-26 | ||
US5871608P | 2008-06-04 | 2008-06-04 | |
US61/058,716 | 2008-06-04 | ||
PCT/GB2008/003945 WO2009068870A1 (en) | 2007-11-26 | 2008-11-26 | Method for producing vaccinal viral strain of a virus of the reoviridae family |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014131862A Division JP5908948B2 (ja) | 2007-11-26 | 2014-06-26 | レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011504367A JP2011504367A (ja) | 2011-02-10 |
JP2011504367A5 JP2011504367A5 (ja) | 2012-01-19 |
JP5619614B2 true JP5619614B2 (ja) | 2014-11-05 |
Family
ID=40290782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010534547A Expired - Fee Related JP5619614B2 (ja) | 2007-11-26 | 2008-11-26 | レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 |
JP2014131862A Active JP5908948B2 (ja) | 2007-11-26 | 2014-06-26 | レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014131862A Active JP5908948B2 (ja) | 2007-11-26 | 2014-06-26 | レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8673315B2 (ja) |
EP (2) | EP2215221B1 (ja) |
JP (2) | JP5619614B2 (ja) |
KR (2) | KR101718497B1 (ja) |
CN (2) | CN101970645B (ja) |
CA (1) | CA2706603C (ja) |
MX (1) | MX2010005701A (ja) |
WO (1) | WO2009068870A1 (ja) |
ZA (1) | ZA201004531B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2792117C (en) * | 2010-03-12 | 2016-09-20 | Merial Limited | Foot and mouth disease virus recombinant vaccines and uses thereof |
MA37749B1 (fr) * | 2012-06-13 | 2017-05-31 | Merial Ltd | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine |
WO2014185784A1 (en) * | 2013-05-16 | 2014-11-20 | Stichting Dienst Landbouwkundig Onderzoek | Vaccines for diseases caused by viruses of the family of reoviridae |
CN109312351B9 (zh) * | 2016-04-26 | 2020-10-23 | 伦敦卫生及热带医学学院 | 呼肠孤病毒科疫苗 |
EP3521426A4 (en) * | 2016-09-27 | 2020-08-12 | Osaka University | PROCESS FOR THE PREPARATION OF ARTIFICIAL RECOMBINANT ROTAVIRUS |
CN109321583B (zh) * | 2018-09-29 | 2023-08-15 | 福建省农业科学院畜牧兽医研究所 | 一种构建番鸭呼肠孤病毒反向遗传系统的方法 |
KR102228267B1 (ko) * | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
WO2020153619A1 (ko) * | 2019-01-25 | 2020-07-30 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100848719B1 (ko) * | 2000-04-28 | 2008-07-25 | 세인트 쥬드 칠드런즈 리써치 호스피탈 | 감염성 인플루엔자 바이러스 생성용 dna 트랜스펙션시스템 |
EP2110382A1 (en) * | 2002-06-20 | 2009-10-21 | Institut Pasteur | Infectious cDNA of an improved vaccine strain of measles virus, use for immunogenic compositions |
CN1563383A (zh) * | 2004-03-17 | 2005-01-12 | 云南出入境检验检疫局检验检疫技术中心 | 蓝舌病病毒vp7基因重组表达质粒载体、vp7表达抗原以及制备方法 |
JP2007215466A (ja) | 2006-02-16 | 2007-08-30 | Fujita Gakuen | レオウイルス科ウイルス由来の組換えウイルスを調製する方法、及び組換えロタウイルス調製用のdnaコンストラクト |
-
2008
- 2008-11-26 MX MX2010005701A patent/MX2010005701A/es active IP Right Grant
- 2008-11-26 WO PCT/GB2008/003945 patent/WO2009068870A1/en active Application Filing
- 2008-11-26 EP EP08854770.8A patent/EP2215221B1/en active Active
- 2008-11-26 CA CA2706603A patent/CA2706603C/en active Active
- 2008-11-26 CN CN200880125535.4A patent/CN101970645B/zh not_active Expired - Fee Related
- 2008-11-26 US US12/744,041 patent/US8673315B2/en not_active Expired - Fee Related
- 2008-11-26 EP EP15199219.5A patent/EP3037526B1/en active Active
- 2008-11-26 KR KR1020107014212A patent/KR101718497B1/ko active IP Right Grant
- 2008-11-26 JP JP2010534547A patent/JP5619614B2/ja not_active Expired - Fee Related
- 2008-11-26 KR KR1020157036407A patent/KR101749130B1/ko active IP Right Grant
- 2008-11-26 CN CN201811285310.7A patent/CN109825517B/zh active Active
-
2010
- 2010-06-25 ZA ZA2010/04531A patent/ZA201004531B/en unknown
-
2014
- 2014-01-28 US US14/166,675 patent/US9457076B2/en active Active
- 2014-06-26 JP JP2014131862A patent/JP5908948B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20100108356A (ko) | 2010-10-06 |
EP2215221A1 (en) | 2010-08-11 |
EP3037526B1 (en) | 2018-03-14 |
EP3037526A3 (en) | 2016-10-05 |
JP5908948B2 (ja) | 2016-04-26 |
CN101970645A (zh) | 2011-02-09 |
US20100322971A1 (en) | 2010-12-23 |
JP2011504367A (ja) | 2011-02-10 |
KR101749130B1 (ko) | 2017-06-20 |
KR20160003896A (ko) | 2016-01-11 |
AU2008331293A1 (en) | 2009-06-04 |
CN109825517B (zh) | 2023-04-14 |
CN109825517A (zh) | 2019-05-31 |
US9457076B2 (en) | 2016-10-04 |
CN101970645B (zh) | 2018-11-30 |
US8673315B2 (en) | 2014-03-18 |
JP2014239683A (ja) | 2014-12-25 |
WO2009068870A1 (en) | 2009-06-04 |
EP3037526A2 (en) | 2016-06-29 |
ZA201004531B (en) | 2011-03-30 |
MX2010005701A (es) | 2010-08-31 |
EP2215221B1 (en) | 2016-02-17 |
CA2706603A1 (en) | 2009-06-04 |
KR101718497B1 (ko) | 2017-03-22 |
US20140134209A1 (en) | 2014-05-15 |
CA2706603C (en) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5908948B2 (ja) | レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法 | |
JP6845266B2 (ja) | 多価組換型鳥ヘルペスウイルス及び鳥類を免疫化するためのワクチン | |
Boyce et al. | Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts | |
JP6246985B1 (ja) | 改良されたhvtベクターnd−ibdワクチン | |
JP5758632B2 (ja) | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 | |
US10206994B2 (en) | RNA virus attenuation by alteration of mutational robustness and sequence space | |
WO2020258757A1 (zh) | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 | |
CN101586120B (zh) | 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体 | |
JP2019524154A (ja) | アヒル腸炎ウイルス及びその使用 | |
CN109136200A (zh) | 一种重组传染性造血器官坏死病毒及其构建方法与应用 | |
AU2014201189B2 (en) | Method for producing vaccinal viral strain of a virus of the Reoviridae family | |
US20240252616A1 (en) | Live-attenuated virus vaccine | |
JP2013055940A (ja) | 組換えノビラブドウイルスおよびその使用 | |
AU2008331293B2 (en) | Method for producing vaccinal viral strain of a virus of the Reoviridae family | |
Liu | Generating a new vaccine for protecting poultry from Newcastle disease and controlling viral shedding | |
CN116814563A (zh) | 一种鸭肠炎病毒毒株及其制备方法与应用 | |
Boyce | Bluetongue virus reverse genetics | |
Janowicz | Molecular determinants of bluetongue virus virulence | |
Islam et al. | Molecular cloning of a Bangladeshi strain of very virulent infectious bursal disease virus of chickens and its adaptation in tissue culture by site-directed mutagenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131203 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140627 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140722 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140829 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140917 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5619614 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |